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Koebner phenomenon and vitiligo
In this retrospective observational cohort study, 700 patients 
with vitiligo were evaluated using a new assessment method for 
Koebner phenomenon (KP). KP1 was positive in 34.1% of the 
patients, 66.3% were KP2A positive and 15.1% were classified 
as KP2B. The body surface area was significantly (P < 0.001) 
higher in the presence of any KP subtype and more disease 
activity was found in KP1-positive and KP2B-positive patients. 
An earlier age at onset and elevated risk of further depigmenta-
tion despite treatment were observed in all KP-positive groups. 
The new assessment method for KP, taking into account both 
history and clinical examination, seems to be a useful and 
valuable tool for assessing KP in daily practice. Results support 
the hypothesis that KP may function as a clinical parameter to 
assess and predict the clinical profile and course of vitiligo. Br J 
Dermatol 2012; 167: 1017–24.
Cutaneous manifestations of dabrafenib 
(GSK2118436)
In this study, a cohort of patients enrolled in the phase I/II trials of 
dabrafenib was followed for the development of cutaneous side-
effects. Thirty-eight patients (93%) developed new skin lesions 
while receiving dabrafenib. The most frequent cutaneous lesions 
observed were of keratinocytic origin and included verrucal 
keratoses (49%), squamous cell carcinoma (SCC) (20%), Grover 
disease (27%), seborrhoeic keratoses (34%), plantar hyperkera-
tosis (22%), hyperkeratotic actinic keratoses (10%) and verruca 
vulgaris (5%). Most SCCs appeared between weeks 6 and 24 
following commencement of therapy on both sun-damaged 
and non-sun-damaged skin. HPV (human papillomavirus) was 
negative in 15 of the 16 tissues studied and p16 expression was 
higher in SCCs compared with verrucal keratoses. Patients need 
careful monitoring for the development of SCCs during treat-
ment with dabrafenib in particular between weeks 6 and 24 of 
treatment. Br J Dermatol 2012; 167: 1153–60.
Ro/SS-A antibody as a possible marker for 
malignancy
Consecutive patients (n = 303) with Ro/SS-A antibody positivity 
were collected over 11 years and were retrospectively analysed. 
Fifty (16.5%) patients were diagnosed with malignancies; 33 
(66%) of these patients had systemic lupus erythematosus or 
cutaneous lupus erythematosus (CLE). Ro/SS-A antibody was 
strongly associated with malignancy, particularly melanoma, 
T-cell lymphoma, non-Hodgkin lymphoma and breast car-
cinoma. Logistic regression modeling revealed that Ro/SS-A 
antibody-positive patients aged 55 years or older, presenting with 
fever, anaemia and CLE, have a greater probability of developing 
malignancy and are considered high-risk patients, compared 
with Ro/SS-A antibody-positive patients with none of the men-
tioned clinical criteria. Br J Dermatol 2012; 167: 1067–75.
Prognosis of PCBCL subtypes
During the period 1987–2009, consecutive patients with pri-
mary cutaneous B-cell lymphomas (PCBCL) were identified 
from the Nottingham Lymphoma Registry. The 5- and 10-year 
lymphoma-specific survival for patients with marginal zone 
lymphoma was 100%. The only patient with intravascular 
large B-cell lymphoma died from widespread disease in spite 
of chemotherapy. The 4-year lymphoma-specific survival for 
follicle centre cell lymphoma was 90%. Patients with the 
other subtypes had the following 5-year lymphoma-specific 
survival rates: diffuse large B cell, leg type, 61% and diffuse 
large B cell, other, 40%. PCBCL is a rare disease and the 
authors stress the importance of diagnosis by a pathologist 
with an interest in cutaneous lymphoma and that the treating 
clinician appreciates the different prognosis of the subtypes. 
Br J Dermatol 2012; 167: 1118–23.
